Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
01 10 2020
Historique:
received: 03 07 2020
accepted: 03 08 2020
pubmed: 5 8 2020
medline: 20 2 2021
entrez: 5 8 2020
Statut: ppublish

Résumé

Pheochromocytomas and paragangliomas (PPGLs) are characterized by distinct genotype-phenotype relationships according to studies largely restricted to Caucasian populations. To assess for possible differences in genetic landscapes and genotype-phenotype relationships of PPGLs in Chinese versus European populations. Cross-sectional study. 2 tertiary-care centers in China and 9 in Europe. Patients with pathologically confirmed diagnosis of PPGL, including 719 Chinese and 919 Europeans. Next-generation sequencing performed in tumor specimens with mutations confirmed by Sanger sequencing and tested in peripheral blood if available. Frequencies of mutations were examined according to tumor location and catecholamine biochemical phenotypes. Among all patients, higher frequencies of HRAS, FGFR1, and EPAS1 mutations were observed in Chinese than Europeans, whereas the reverse was observed for NF1, VHL, RET, and SDHx. Among patients with apparently sporadic PPGLs, the most frequently mutated genes in Chinese were HRAS (16.5% [13.6-19.3] vs 9.8% [7.6-12.1]) and FGFR1 (9.8% [7.6-12.1] vs 2.2% [1.1-3.3]), whereas among Europeans the most frequently mutated genes were NF1 (15.9% [13.2-18.6] vs 6.6% [4.7-8.5]) and SDHx (10.7% [8.4-13.0] vs 4.2% [2.6-5.7]). Among Europeans, almost all paragangliomas lacked appreciable production of epinephrine and identified gene mutations were largely restricted to those leading to stabilization of hypoxia inducible factors. In contrast, among Chinese there was a larger proportion of epinephrine-producing paragangliomas, mostly due to HRAS and FGFR1 mutations. This study establishes Sino-European differences in the genetic landscape and presentation of PPGLs, including ethnic differences in genotype-phenotype relationships indicating a paradigm shift in our understanding of the biology of these tumors.

Identifiants

pubmed: 32750708
pii: 5880618
doi: 10.1210/clinem/dgaa502
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Epinephrine YKH834O4BH

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Jingjing Jiang (J)

Department of Endocrinology and Metabolism, Zhongshan Hospital, Shanghai, China.
Fudan Institute for Metabolic Diseases, Fudan University, Shanghai, China.

Jing Zhang (J)

Department of Endocrinology and Metabolism, Zhongshan Hospital, Shanghai, China.
Fudan Institute for Metabolic Diseases, Fudan University, Shanghai, China.

Yingxian Pang (Y)

Department of Urology, Xiangya Hospital, Central South University, Changsha, China.

Nicole Bechmann (N)

Institute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Germany.
Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany.
German Institute of Human Nutrition Potsdam-Rehbruecke, Department of Experimental Diabetology, Nuthetal, Germany.
German Center for Diabetes Research, München-Neuherberg, Germany.

Minghao Li (M)

Department of Urology, Xiangya Hospital, Central South University, Changsha, China.
Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany.

Maria Monteagudo (M)

Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center and Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.

Bruna Calsina (B)

Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center and Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.

Anne-Paule Gimenez-Roqueplo (AP)

Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Genetics Department, Paris, France.
Université de Paris, PARCC, INSERM, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.

Svenja Nölting (S)

Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany.

Felix Beuschlein (F)

Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany.
Department of Endocrinology, Diabetology and Clinical Nutrition, Univiersitäts Spital Zürich, Zurich, Switzerland.

Martin Fassnacht (M)

Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.

Timo Deutschbein (T)

Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.

Henri J L M Timmers (HJLM)

Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.

Tobias Åkerström (T)

Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.

Joakim Crona (J)

Department of medical sciences, Uppsala University, Uppsala, Sweden.

Marcus Quinkler (M)

Endocrinology in Charlottenburg, Berlin, Germany.

Stephanie M J Fliedner (SMJ)

First Department of Medicine, University Medical Center Schleswig-Holstein, Lübeck, Germany.

Yujun Liu (Y)

Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.

Jianming Guo (J)

Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.

Xiaomu Li (X)

Department of Endocrinology and Metabolism, Zhongshan Hospital, Shanghai, China.
Fudan Institute for Metabolic Diseases, Fudan University, Shanghai, China.

Wei Guo (W)

Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.

Yingyong Hou (Y)

Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.

Cikui Wang (C)

Department of Urology, Xiangya Hospital, Central South University, Changsha, China.

Liang Zhang (L)

Department of Urology, Xiangya Hospital, Central South University, Changsha, China.

Qiao Xiao (Q)

Department of Urology, Xiangya Hospital, Central South University, Changsha, China.

Longfei Liu (L)

Department of Urology, Xiangya Hospital, Central South University, Changsha, China.

Xin Gao (X)

Department of Endocrinology and Metabolism, Zhongshan Hospital, Shanghai, China.
Fudan Institute for Metabolic Diseases, Fudan University, Shanghai, China.

Nelly Burnichon (N)

Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Genetics Department, Paris, France.
Université de Paris, PARCC, INSERM, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.

Mercedes Robledo (M)

Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center and Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.

Graeme Eisenhofer (G)

Institute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Germany.
Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH